TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01352715
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
Study: NCT01352715
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
Study: NCT01352715
Drug: Emtricitabine/tenofovir disoproxil fumarate
Normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
Study: NCT01352715
Drug: Abacavir/lamivudine/zidovudine
Normalized name: ABACAVIR/LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
Study: NCT01352715
Drug: Abacavir/lamivudine
Normalized name: ABACAVIR/LAMIVUDINE
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
Study: NCT01352715
Drug: Lamivudine/zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
Study: NCT01352715
Drug: Abacavir
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
Study: NCT01352715
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
Study: NCT00077727
Drug: Extended-release galantamine hydrobromide
Normalized name: galantamine hydrobromide Extended Release Oral Capsule
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01352715
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
Study: NCT01310452
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: insulin detemir once daily with metformin
Study: NCT01310452
Drug: neutral protamine insulin
Normalized name: Neutral Protamine Hagedorn (NPH) insulin
DrugBank: Protamine sulfate (DB09141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: neutral protamine insulin once daily with metformin
Study: NCT01328132
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
Study: NCT01339143
Drug: Galvus (vildagliptin)
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 50mg BID, PO, for 16 weeks
Study: NCT01339143
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg, QD, PO, 16 weeks
Study: NCT02132026
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02132026
Drug: Denosumab Placebo
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subcutaneous injection of 0.9%Saline at baseline, 6 months, 12 months and 18 months
Study: NCT01497496
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
Study: NCT01497496
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
Study: NCT00095888
Drug: triapine
Normalized name: Triapine
DrugBank: Triapine (DB11940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00095888
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02295124
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive oxycodone 10mg (5mg if \> 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
Study: NCT00469599
Drug: paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
Study: NCT00469599
Drug: alfacalcidol
Normalized name: Alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
Study: NCT02871986
Drug: Routine transdermal oestrogen patch
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestrogen patch will be used with an incremental dose increase at 4 months
Study: NCT02431637
Drug: Piperaquine Phosphate 480 mg
Normalized name: Piperazine
DrugBank: Piperaquine (DB13941)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
Study: NCT02295124
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an initial dose of hydromorphone 2mg (1mg if \> 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
Study: NCT01206296
Drug: Intraperitoneal Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles
Study: NCT00158002
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00953849
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
Study: NCT03146416
Drug: Evinacumab
Normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SC or IV administration of Evinacumab
Study: NCT02952820
Drug: lemborexant
Normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00953849
Drug: Celecoxib plus Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
Study: NCT02319018
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02319018
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03791814
Drug: Zepatier
Normalized name: Zepatier
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients screened as HCV positive will receive Zepatier for 12 weeks.
Study: NCT04139018
Drug: Timolol Gel
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5) and 0.5 ml applied to each nostril twice daily. The total daily dose would amount to 2 mg.
Study: NCT02247986
Drug: Methylphenidate Hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bold signal changes by methylphenidate on DBD
Study: NCT01040910
Drug: smoking of cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
Study: NCT04171843
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is used for lymphodepletion.
Study: NCT02010359
Drug: Lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza 4 grams per day
Study: NCT02849873
Drug: Tazorac Cream
Normalized name: tazarotene Topical Cream [Tazorac]
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream
Study: NCT04731740
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PO
Study: NCT02058940
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
Study: NCT04171843
Drug: Nirogacestat
Normalized name: NIROGACESTAT
DrugBank: Nirogacestat (DB12005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic anti-BCMA CAR T-cell
Study: NCT02779101
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg every 3 weeks
Study: NCT03123627
Drug: Profilaxis recommended
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ\> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
Study: NCT02157883
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
Study: NCT00327600
Drug: imexon
Normalized name: Imexon
DrugBank: Imexon (DB05003)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00327600
Drug: DTIC
Normalized name: DTIC
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01925456
Drug: Toviaz
Normalized name: Toviaz
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
Study: NCT01767090
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous
Study: NCT04335006
Drug: Carelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants receive SHR-1210 intravenously (IV)
Study: NCT04335006
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered intravenously every 4-week cycle
Study: NCT04335006
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally every 4-week cycle
Study: NCT00196482
Drug: changing of fortifier
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003876
Drug: polifeprosan 20 with carmustine implant
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01789476
Drug: CR845
Normalized name: Difelikefalin
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
Study: NCT01524575
Drug: gemcitabine and oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts.
Study: NCT02951377
Drug: Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).
Study: NCT00967070
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
Study: NCT04393454
Drug: Sirolimus 2mg Tablet
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (oral) will be started at 2 mg daily. Sirolimus dosing will be titrated to meet serum trough levels of \>8 ng/ml, assayed at 7 days after starting a new dose, by chromatography/mass spectrometry. Once adequate serum levels are met (≥8 ng/ml), the same dosing will be continued until progression of disease as evidenced by imaging, or unacceptable toxicity.
Study: NCT02822729
Drug: DE-117 ophthalmic solution
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02822729
Drug: Timolol ophthalmic solution
Normalized name: timolol Ophthalmic Solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04085562
Drug: Bisoprolol Fumarate 5-10 mg
Normalized name: bisoprolol fumarate 10 MG
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol as antihypertensive drug in patients on hemodialysis
Study: NCT04085562
Drug: Amlodipine 5-10 mg
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine as antihypertensive drug in patients on hemodialysis
Study: NCT00103389
Drug: PI-88
Normalized name: Heparanase inhibitor PI-88
DrugBank: Muparfostat (DB05808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-88+docetaxel
Study: NCT00103389
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel only
Study: NCT00542165
Drug: Alfuzosin
Normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02132065
Drug: TAP block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
Study: NCT03857425
Drug: Clostridum Butyricum Capsule
Normalized name: Butyricum acidum
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridum Butyricum Capsule 3\*420mg,twice daily for 8 weeks
Study: NCT03857425
Drug: Bacillus Coagulans Tablets
DrugBank: Bacillus coagulans (DB19246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
Study: NCT03857425
Drug: Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets
Normalized name: Bacillus coagulans Oral Capsule
DrugBank: Bacillus coagulans (DB19246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
Study: NCT01229865
Drug: VB-111
Normalized name: VB-201
DrugBank: VB-201 (DB15259)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00594334
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly Risedronate
Study: NCT00807651
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
Study: NCT03252808
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
Study: NCT03252808
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/m\^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
Study: NCT03252808
Drug: TS-1
Normalized name: CTS-1027
DrugBank: Gimeracil (DB09257)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
Study: NCT02713893
Drug: Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02713893
Drug: Placebo plus Econazole nitrate 1% intravaginal cream
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02713893
Drug: Placebo plus Benzydamine HCl 0.12% intravaginal cream
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01741558
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
Study: NCT02917096
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02917096
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02917096
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02917096
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02917096
Drug: Ruxolitinib Phosphate
Normalized name: Ruxolitinib Phosphate
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02917096
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02917096
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV and PO
Study: NCT04173520
Drug: DDA
Normalized name: BDDA
DrugBank: Treamid (DB16365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow up after SVR
Study: NCT00405925
Drug: Trizivir
Normalized name: Trizivir
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00405925
Drug: zidovudine,lamivudine,abacavir
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
Study: NCT01851642
Drug: Albuterol inhaler.
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
Study: NCT00161759
Drug: Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01039740
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine administration for 6 weeks under therapeutic dose
Study: NCT04262843
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04262843
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04262843
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immunosuppressive therapy
Study: NCT04262843
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunosuppressive therapy
Study: NCT01558466
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.